Respiratory Pipeline
At GSK, our pipeline is focused on unlocking the science of the immune system, human genetics, and advanced technologies to develop vaccines and specialty medicines.
Our products in development progress through three stages: phase I, phase II, and phase III/registrational. Each of these phases allows us to assess the safety and efficacy of our investigational products to eventually provide data to support applications for regulatory approval.
Copy Page URL
Anti-TSLP (GSK5784283)
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
Go to ResourceLong-acting IL-5 antagonist (depemokimab)
NIMBLE: A Study of Depemokimab Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
Go to ResourceAn Open-Label Extension Study of Depemokimab in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
Go to ResourceICS/LAMA/LABA (fluticasone furoate/umeclidinium/vilanterol)
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
Go to ResourceLong-acting IL-5 antagonist (depemokimab)
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
Go to ResourceAnti-IL33 (GSK3862995B)
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
Go to ResourceAnti-IL33 (GSK3862995B)
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Go to ResourceLong-acting IL-5 antagonist (depemokimab)
Endura-1: Depemokimab as an Extended treatment Duration Biologic in Adults With COPD and Type 2 Inflammation
Go to ResourceEndura-2: Depemokimab as an Extended treatment Duration Biologic in Adults With COPD and Type 2 Inflammation
Go to ResourceVigilant: Evaluating the Efficacy and Safety of Initiating DepemokImab Early Therapy in COPD With Type 2 Inflammation
Go to ResourceAnti-BLyS (belimumab)
BEconneCTD-ILD: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Go to ResourceLong-acting IL-5 antagonist (depemokimab)
OCEAN: Efficacy and Safety of Depemokimab Compared with Mepolizumab in Adults with Relapsing or Refractory EGPA
Go to ResourceIL-5 antagonist
SPHERE: Study in Pediatrics with HypEREosinophilic Syndrome
Go to ResourceLong-acting IL-5 antagonist (depemokimab)
DESTINY: Depemokimab in Participants with HES, Efficacy, and Safety Trial
Go to ResourceAnti-IL33 (GSK3862995B)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
Go to ResourceP2X3 Antagonist (camlipixant [BLU-5937])
CALM-1: A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults with Refractory Chronic Cough
Go to ResourceCALM-2: A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults with Refractory Chronic Cough
Go to ResourceAnti-BLyS (belimumab)
BLISSc-ILD: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Go to ResourceAnti-BLyS (belimumab)
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Go to ResourceUse filter to search Pipeline
Disclaimer
This document contains information for healthcare providers and is intended solely for educational purposes. This display includes ongoing clinical trials for both approved and investigational compounds.
Some agents are approved in select indications. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov.